专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009075923A2 6, 11-BRIDGED BIARYL MACROLIDES 审中-公开
标题翻译： 6,11-BRIDGED BIARYL MACROLIDES
公开(公告)号：WO2009075923A2
公开(公告)日：2009-06-18
申请号：PCT/US2008/076731
申请日：2008-09-17
申请人： ENANTA PHARMACEUTICALS, INC. , KIM, In, Jong , LIU, Tongzhu , LONG, Jiang , WANG, Guoqiang , QUI, Yao-ling , KIM, Heejin , WANG, Yanchun , PHAN, Ly, Tam , OR, Yat, Sun
发明人： KIM, In, Jong , LIU, Tongzhu , LONG, Jiang , WANG, Guoqiang , QUI, Yao-ling , KIM, Heejin , WANG, Yanchun , PHAN, Ly, Tam , OR, Yat, Sun
IPC分类号： C07H17/08 , A61K31/7052
CPC分类号： C07H17/08 , C07D213/69 , C07D213/80 , C07D309/40 , C07D498/12
摘要： The present invention discloses compounds of formula I, II or, or pharmaceutically acceptable salts, esters, or prodrugs thereof: (formulas) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
摘要翻译：本发明公开了式I，II或其药学上可接受的盐，酯或前药的化合物：表现出抗菌特性的式（式）。本发明还涉及包含前述化合物的药物组合物，用于向需要抗生素治疗的受试者施用。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。本发明还包括制备本发明化合物的方法。

2. 发明申请

WO2012125900A1 2'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES 审中-公开
标题翻译： 2'-烯替代的核苷酸衍生物
公开(公告)号：WO2012125900A1
公开(公告)日：2012-09-20
申请号：PCT/US2012/029381
申请日：2012-03-16
申请人： ENANTA PHARMACEUTICALS, INC. , OR, Yat, Sun , MA, Jun , WANG, Guoqiang , KIM, In, Jong , LONG, Jiang , QIU, Yao-Ling
发明人： OR, Yat, Sun , MA, Jun , WANG, Guoqiang , KIM, In, Jong , LONG, Jiang , QIU, Yao-Ling
IPC分类号： A01N43/04 , A61K31/70
CPC分类号： C07H19/06 , A61K31/7056 , A61K31/706 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K38/55 , A61K45/06 , A61K2300/00 , A61K31/426 , A61K31/13
摘要： The present invention relates to 2'-allene-substituted nucleoside derivatives of the general formula (I): As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related β-D and β-L-nucleoside derivatives.
摘要翻译：本发明涉及通式（I）的2'-连烯取代的核苷衍生物：以及包含这些化合物的药物组合物以及治疗或预防HIV感染，HBV感染，HCV感染或异常细胞增殖的方法，包括给药所述化合物或组合物。此外，本发明包括制备这些化合物的方法，以及相关的β-D和β-L-核苷衍生物。

3. 发明申请

WO2009003009A1 SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES 审中-公开
标题翻译：替代吡咯烷作为抗感染剂
公开(公告)号：WO2009003009A1
公开(公告)日：2008-12-31
申请号：PCT/US2008/068130
申请日：2008-06-25
申请人： ENANTA PHARMACEUTICALS, INC. , OR, Yat, Sun , YING, Lu , WANG, Ce , LONG, Jiang , QUI, Yao-Ling
发明人： OR, Yat, Sun , YING, Lu , WANG, Ce , LONG, Jiang , QUI, Yao-Ling
IPC分类号： A61K31/4025 , C07D403/06
CPC分类号： C07D417/14 , A61K38/21 , C07D401/14 , C07D403/06 , C07D405/14 , C07D409/14 , C07D413/04 , C07D417/04 , A61K2300/00
摘要： The present invention discloses compounds of Formulae (A), or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (A), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV infection in a subject in need of such therapy with said compounds.
摘要翻译：本发明公开了式（A）或其药学上可接受的盐，酯或前药的化合物：抑制含RNA病毒，特别是丙型肝炎病毒（HCV）的式（A）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物，包含这些化合物的药物组合物，以及用于治疗或预防病毒（特别是需要用所述化合物治疗的受试者的HCV感染）的方法。

4. 发明申请

WO2010088573A1 CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION 审中-公开
标题翻译：用于预防或治疗丙型肝炎感染的环磷酰胺类似物
公开(公告)号：WO2010088573A1
公开(公告)日：2010-08-05
申请号：PCT/US2010/022675
申请日：2010-01-30
申请人： ENANTA PHARMACEUTICALS, INC. , OR, Yat, Sun , WANG, Guoqiang , LONG, Jiang , GAO, Xuri
发明人： OR, Yat, Sun , WANG, Guoqiang , LONG, Jiang , GAO, Xuri
IPC分类号： A61K38/13
CPC分类号： A61K38/13 , A61K31/7088 , A61K38/21 , A61K45/00 , A61K45/06 , C07K7/52 , C07K7/645 , Y02A50/463
摘要： The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
摘要翻译：本发明涉及对HCV具有抗病毒活性的环孢菌素类似物，可用于治疗HCV感染。更具体地，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。

5. 发明申请

WO2012040167A1 MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS 审中-公开
标题翻译：大环丙糖衍生的HCV丝氨酸蛋白酶抑制剂
公开(公告)号：WO2012040167A1
公开(公告)日：2012-03-29
申请号：PCT/US2011/052304
申请日：2011-09-20
申请人： ENANTA PHARMACEUTICALS, INC. , OR, Yat Sun , MA, Jun , WANG, Guoqiang , LONG, Jiang , WANG, Bin
发明人： OR, Yat Sun , MA, Jun , WANG, Guoqiang , LONG, Jiang , WANG, Bin
IPC分类号： A61K38/21
CPC分类号： C07K5/123 , A61K38/00 , A61K38/12 , A61K45/06 , C07K5/06034 , C07K5/0808 , C07K5/0823 , C07K5/0827 , C07K14/811
摘要： The present invention discloses compounds of Formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式（I）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

6. 发明申请

WO2015031381A1 CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C 审中-公开
标题翻译：用于预防或治疗HEPATITIS的环磷酰胺类似物C
公开(公告)号：WO2015031381A1
公开(公告)日：2015-03-05
申请号：PCT/US2014/052740
申请日：2014-08-26
申请人： ENANTA PHARMACEUTICALS, INC.
发明人： OR, Yat, Sun , WANG, Guoqiang , LONG, Jiang , KIM, In, Jong
IPC分类号： A61K31/7088 , A61K38/13 , C07K7/52
CPC分类号： A61K38/13 , A61K38/00 , A61K38/21 , A61K45/06 , C07K7/645 , Y02A50/463 , A61K2300/00
摘要： The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
摘要翻译：本发明涉及对HCV具有抗病毒活性的新型环孢菌素类似物，可用于治疗HCV感染。更具体地，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。

7. 发明申请

WO2013059281A2 PROCESSES FOR THE PREPARATION OF NOVEL BENZIMIDAZOLE DERIVATIVES 审中-公开
标题翻译：制备新型苯并咪唑衍生物的方法
公开(公告)号：WO2013059281A2
公开(公告)日：2013-04-25
申请号：PCT/US2012/060560
申请日：2012-10-17
申请人： ENANTA PHARMACEUTICALS, INC.
发明人： TANG, Datong , XU, Guoyou , PENG, Xiaowen , YING, Lu , WANG, Ce , CAO, Hui , LONG, Jiang , KIM, In, Jong , WANG, Guoqiang , QIU, Yao-ling , OR, Yat, Sun
IPC分类号： C07D403/14
CPC分类号： C07D403/14
摘要： The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatits C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a):
摘要翻译：本发明涉及用于制备新的苯并咪唑衍生物的方法和中间体，特别是在肝素C病毒NS5A抑制剂的合成中。特别地，本发明涉及制备式（I-a）化合物的方法和中间体：

8. 发明申请

WO2023023310A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2023023310A1
公开(公告)日：2023-02-23
申请号：PCT/US2022/040861
申请日：2022-08-19
申请人： ENANTA PHARMACEUTICALS, INC.
发明人： WANG, Guoqiang , MA, Jun , GRANGER, Brett , LONG, Jiang , WANG, Bin , GHORAI, Sourav , HE, Jing , HE, Yong , XING, Xuechao , SHEN, Ruichao , OR, Yat, Sun
IPC分类号： A61K31/18 , A61K31/63 , C07C311/08
摘要： The present invention provides compounds of Formula (I), pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.

9. 发明申请

WO2022109363A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS 审中-公开
公开(公告)号：WO2022109363A1
公开(公告)日：2022-05-27
申请号：PCT/US2021/060247
申请日：2021-11-22
申请人： ENANTA PHARMACEUTICALS, INC.
发明人： WANG, Guoqiang , SHEN, Ruichao , HE, Yong , MA, Jun , XING, Xuechao , CAO, Hui , GAO, Xuri , PENG, Xiaowen , LONG, Jiang , LI, Wei , ZHANG, Jiajun , PANARESE, Joseph, D. , KENTON, Nathaniel, Thomas , BARTLETT, Samuel , OR, Yat, Sun
IPC分类号： A61K31/554 , A61P31/20 , C07D515/20
摘要： The present invention discloses compounds of Formula (la), and pharmaceutically acceptable salts, thereof: Formula (Ia) which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (la) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (la) or a pharmaceutically acceptable salt thereof.

10. 发明申请

WO2018218051A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2018218051A1
公开(公告)日：2018-11-29
申请号：PCT/US2018/034441
申请日：2018-05-24
申请人： ENANTA PHARMACEUTICALS, INC.
发明人： GRANGER, Brett , WANG, Guoqiang , SHEN, Ruichao , HE, Jing , HE, Yong , XING, Xuechao , MA, Jun , LONG, Jiang , OR, Yat, Sun , WANG, Bin
IPC分类号： A61K31/4439 , A61K45/06 , A61K9/00
摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式